Status:
COMPLETED
Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer
Lead Sponsor:
Mayo Clinic
Conditions:
Breast Carcinoma
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer. QTI is...
Eligibility Criteria
Inclusion
- Women 18+ years of age
- High lifetime risk of breast cancer as determined by a risk assessment tool such a Tyrer-Cuzick model
- Clinical ordered screening MRI.
- MRI and QTI performed within 30 days of each other
- Breasts that will fit in the quantitate transmission (QT) Ultrasound Breast Scanner (e.g. bra cup size less than DDD)
Exclusion
- Pregnant patients
- Lactating patients
- Patients with open wounds or discharge
- Patients \< 18 years of age
- Patients who are \> 350 lbs
- Patients who are unable to lay prone for \>15 minutes
Key Trial Info
Start Date :
July 31 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 20 2025
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT07216274
Start Date
July 31 2025
End Date
October 20 2025
Last Update
December 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905